Existing NEU1 inhibitors (antiviral drugs such as zanamivir and oseltamivir) have good safety and pharmacokinetic properties and may be used to ameliorate mitochondrial metabolism and oxidative stress in myocardial infarction or heart failure. Here, NEU1 is linked to myocardial infarction.